Adage Capital Partners Gp, L.L.C. Adverum Biotechnologies, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $5.15 Million - $10.8 Million	-500,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $11.1 Million - $33.3 Million	-1,300,000 Reduced 72.22%	500,000 $10.4 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $6.38 Million - $13.1 Million	800,000 Added 80.0%	1,800,000 $17.6 Million
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $10.5 Million - $31.8 Million	-2,000,000 Reduced 66.67%	1,000,000 $5.45 Million
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $4.5 Million - $7.6 Million	-1,000,000 Reduced 25.0%	3,000,000 $18.2 Million
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $2.65 Million - $3.45 Million	500,000 Added 14.29%	4,000,000 $21.2 Million
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $3.65 Million - $7.95 Million	1,000,000 Added 40.0%	3,500,000 $20.3 Million
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $1.43 Million - $1.98 Million	500,000 Added 25.0%	2,500,000 $8.75 Million
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.65 $4.9 Million - $7.3 Million	2,000,000	2,000,000 $7.3 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $660M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.